phase III trial should be announced very soon and then the countdown will begin. Deutsche Bank, the lead underwriter of the recent secondary still hasn't initiated coverage and my guess is they will very soon.
I wasn't referring to the phase 3 results, but the completion of enrollment of the phase 3 trial. Shortly after that is announced, many subscription based biotech trading sites will recommed their subscribers to start buying for the runup to the phase 3 results.
I do think DB will initiate coverage not long after enrollment has been completed.